Roche has announced a $50 billion investment in the United States over the next five years to expand its pharmaceutical and diagnostics operations. The investment will support upgrades and new construction at existing and planned sites across eight states, generating over 12,000 new jobs, including 6,500 in construction and 1,000 at new or expanded facilities. The company will enhance its manufacturing and distribution capabilities in Kentucky, Indiana, New Jersey, Oregon, and California; build a gene therapy manufacturing plant in Pennsylvania; and establish a 900,000 square foot production center for weight loss therapies. Roche will also construct a continuous glucose monitoring site in Indiana and a new research center in Massachusetts focused on AI and cardiometabolic conditions.
With a current U.S. workforce of more than 25,000 across 24 sites, Roche aims to strengthen its presence in the country’s life sciences sector. The company also plans significant upgrades to R&D sites in Arizona, Indiana, and California. CEO Thomas Schinecker stated, “We are proud of our 110 year legacy in the United States, which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.” Once the new facilities are fully operational, Roche expects to export more medicines from the U.S. than it imports, expanding its diagnostics and pharmaceutical impact globally.
